Overview

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults with developmental and epileptic encephalopathies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Longboard Pharmaceuticals